Michael Barbella, Managing Editor12.08.22
The U.S. Patent and Trademark Office has issued ENDRA Life Sciences Inc. two new ENDRA-related patents.
U.S. Patent No. 11456518 (the ‘518 patent) is titled, “Method for Manufacturing a Radio Frequency Applicator,” and U.S. Patent No. 11478153 (the ‘153 patent) is called “System for Monitoring Tissue Temperature.”
“We are pleased with the issuance of our 32nd and 33rd patents in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," ENDRA's Chairman and CEO Francois Michelon stated. "We continue to strengthen our intellectual property portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 56 patents issued globally.”
The ‘518 patent provides further intellectual property protection for the company's TAEUS platform related to its disruptive scanning approach. It covers a method for manufacturing a radio frequency (RF) applicator device that is used to provide reliable RF energy in a target region of tissue. Specifically, the '518 patent further defines ENDRA's solution to provide targeted RF energy to tissue regions for certain applications, such as fat quantification of a patient's liver. The ‘518 patent is linked to its parent, which covers embodiments of the RF applicator device.
The ‘153 patent relates to the TAEUS system monitoring tissue temperature during surgical procedures. ENDRA expects its system to be effective for both thermotherapy and cryotherapy procedures. The ‘153 patent is linked to its parent, which covers complementary method embodiments.
ENDRA Life Sciences developed Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 500,000 ultrasound systems currently in use. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
U.S. Patent No. 11456518 (the ‘518 patent) is titled, “Method for Manufacturing a Radio Frequency Applicator,” and U.S. Patent No. 11478153 (the ‘153 patent) is called “System for Monitoring Tissue Temperature.”
“We are pleased with the issuance of our 32nd and 33rd patents in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," ENDRA's Chairman and CEO Francois Michelon stated. "We continue to strengthen our intellectual property portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 56 patents issued globally.”
The ‘518 patent provides further intellectual property protection for the company's TAEUS platform related to its disruptive scanning approach. It covers a method for manufacturing a radio frequency (RF) applicator device that is used to provide reliable RF energy in a target region of tissue. Specifically, the '518 patent further defines ENDRA's solution to provide targeted RF energy to tissue regions for certain applications, such as fat quantification of a patient's liver. The ‘518 patent is linked to its parent, which covers embodiments of the RF applicator device.
The ‘153 patent relates to the TAEUS system monitoring tissue temperature during surgical procedures. ENDRA expects its system to be effective for both thermotherapy and cryotherapy procedures. The ‘153 patent is linked to its parent, which covers complementary method embodiments.
ENDRA Life Sciences developed Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 500,000 ultrasound systems currently in use. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.